Dermapharm Reports Profitable Growth in H1 2026

Dermapharm Holding SE announced a successful first half of 2026, with consolidated revenue rising by 2.9% to EUR 591.0 million. The company also reported a 10.3% increase in adjusted EBITDA, reaching EUR 163.2 million, and an improved adjusted EBITDA margin of 27.6%.

The "Branded pharmaceuticals" segment was a key contributor, with revenue up 11.6% driven by organic growth and acquisitions of the Mucos Group and F. Trenka. Despite a decline in revenue in the "Parallel import business," earnings in this segment improved due to strategic focus on high-margin products.

Dermapharm confirmed its guidance for the year, expecting consolidated revenue between EUR 1,182 million and EUR 1,218 million, and adjusted EBITDA between EUR 331 million and EUR 341 million, highlighting its growth strategy and resilient business model.